| __timestamp | Exelixis, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 91733000 |
| Thursday, January 1, 2015 | 57305000 | 87644000 |
| Friday, January 1, 2016 | 116145000 | 92365000 |
| Sunday, January 1, 2017 | 159362000 | 85656000 |
| Monday, January 1, 2018 | 206366000 | 88196000 |
| Tuesday, January 1, 2019 | 228244000 | 89971000 |
| Wednesday, January 1, 2020 | 293355000 | 93413000 |
| Friday, January 1, 2021 | 401715000 | 91355000 |
| Saturday, January 1, 2022 | 459856000 | 113676000 |
| Sunday, January 1, 2023 | 542705000 | 198366000 |
| Monday, January 1, 2024 | 492128000 | 218935000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Exelixis, Inc. and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Exelixis, Inc. has seen a staggering increase in SG&A expenses, growing by over 900%, peaking at approximately $543 million in 2023. In contrast, Taro Pharmaceutical Industries Ltd. has maintained a more stable trajectory, with expenses increasing by about 140% over the same period, reaching nearly $199 million in 2023. This stark contrast highlights Exelixis's aggressive expansion and investment strategies compared to Taro's more conservative approach. Notably, data for Exelixis in 2024 is missing, leaving room for speculation on future trends. Such insights are invaluable for investors and industry analysts alike.
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Taro Pharmaceutical Industries Ltd.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Dr. Reddy's Laboratories Limited and Taro Pharmaceutical Industries Ltd.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and CRISPR Therapeutics AG
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Comparing SG&A Expenses: Veracyte, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights